Pliva Kraków wants to supply the West with drugs

The change is related to the new strategy of its owner, Croatian Pliva, which is the second largest investor in the Polish pharmaceutical sector following its merger with Barr, and the third largest producer of generic drugs in the world. Barr wants to transfer the production of certain drugs from the United States to Kraków. Therefore, in 2008 the company plans to increase employment in its production and R&D departments. The structure of production in the Polish plant is also to change. "Currently 90 percent of drugs manufactured in Poland go to the Polish market and only 10% to Western Europe. We want the proportions to be as follows: 60% to the USA and Western Europe and 40% to Poland. This will begin to change this year," declared Paul M. Bisaro, the president and COO of Barr. (Puls Biznesu, p. 10) E.B.